Rigel Pharmaceuticals, Inc. - RIGL Open Rigel Pharmaceuticals, Inc. in new tab

34.55 USD

P/E

5.82

EPS

5.43

P/B

6.91

ROE

376.09

Beta

1.20

Target Price

38.33 USD

Rigel Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2025

Rigel Pharmaceuticals reported robust financial performance in Q3 2025, achieving record net product sales of $64.1 million, a 65% year-over-year increase, alongside significant advancements in its development pipeline.

Total revenue for Q3 2025 reached $69.5 million, reinforcing strong commercial execution and strategic pipeline expansion.
The company raised its 2025 revenue guidance to a range of $285 million to $290 million, reflecting a growth of 55% to 59% compared to 2024.
Rigel achieved net income of $27.9 million in Q3 and increased cash reserves to $137.1 million, maintaining strong financial discipline.
Key products TAVALISSE, GAVRETO, and REZLIDHIA all demonstrated substantial year-over-year growth, with TAVALISSE alone generating $44.7 million in net sales.

34.5500 USD

34.550 USD

Daily: +0.00%

1M 6M YTD 1Y 2Y 5Y Max

Key Metrics

Earnings date: March 3, 2026

P/E: 5.82

EPS: 5.43

Book Value: 4.57

Price to Book: 6.91

Debt/Equity: 74.50

% Insiders: 2.653%

Growth

Revenue Growth: 1.76%

Earnings Growth: 17.87%

Estimates

Forward P/E: 35.89

Forward EPS: 0.88

Target Mean Price: 38.33

DCF Valuation

Tweak assumptions to recompute fair value for Rigel Pharmaceuticals, Inc. (RIGL)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

About Rigel Pharmaceuticals, Inc. - (RIGL)

Country: United States

Sector: Health Care

Website: http://www.rigel.com

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Exchange Ticker

FRA (Germany) RI2A.F

NMS (United States) RIGL

No dividends available.

Dividends

Historical Split Corporate Actions

Split Date	Split Ratio to 1
June 25, 2003	0.110000
June 27, 2024	0.100000

Trades

My Trades

Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Community Discussion

Twitter YouTube Reddit Roadmap Support Pricing Help

Support email: support@allinvestview.com

Logos provided by Clearbit.

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.

Rigel Pharmaceuticals, Inc. - RIGL Open Rigel Pharmaceuticals, Inc. in new tab

34.5500 USD

34.550 USD

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

About Rigel Pharmaceuticals, Inc. - (RIGL)

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Notifications